Stefan A. Loening

Stefan A. Loening's AcademicInfluence.com Rankings

Stefan A. Loening

Engineering

#7180

World Rank

#8543

Historical Rank

Biomedical Engineering

#698

World Rank

#710

Historical Rank

Applied Physics

#2431

World Rank

#2472

Historical Rank

engineering Degrees

Download Badge

Engineering

Stefan A. Loening's Degrees

PhD Biomedical Engineering Stanford University
Masters Biomedical Engineering Stanford University
Bachelors Biomedical Engineering Stanford University

Why Is Stefan A. Loening Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stefan A. Loening's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial technique (2005) (688)
Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia (2001) (668)
Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. (2007) (456)
Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial (2007) (331)
Complications of laparoscopic procedures in urology: experience with 2,407 procedures at 4 German centers. (1999) (313)
MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. (2005) (271)
Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? (2005) (229)
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). (2004) (219)
Laparoscopic Radical Prostatectomy (2001) (210)
Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. (2005) (194)
Laparoscopic radical cystectomy with continent urinary diversion (rectal sigmoid pouch) performed completely intracorporeally: the initial 5 cases. (2001) (189)
Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. (2002) (187)
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival (2005) (177)
Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model (2005) (173)
Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades (2004) (170)
Carcinoma of the penis. Analysis of 219 cases (1982) (162)
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone (1983) (162)
Laparoscopic dismembered pyeloplasty--the method of choice in the presence of an enlarged renal pelvis and crossing vessels. (2002) (157)
FLUORESCENCE ENDOSCOPY WITH 5-AMINOLEVULINIC ACID REDUCES EARLY RECURRENCE RATE IN SUPERFICIAL BLADDER CANCER (2001) (155)
Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. (2002) (152)
Laparoscopic partial nephrectomy: initial experience and comparison to the open surgical approach. (1995) (152)
Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. (2002) (148)
ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions (2003) (144)
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer (2004) (143)
Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. (2006) (143)
Urological laparoscopic surgery. (1991) (139)
Validity and reliability of the DDS for severity of delirium in the ICU (2005) (134)
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. (2004) (133)
Old‐for‐Old Kidney Allocation Allows Successful Expansion of the Donor and Recipient Pool (2003) (127)
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. (2000) (120)
Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer (2000) (119)
High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trial. (1998) (118)
Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer (2000) (113)
The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia (1997) (112)
Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. (2006) (112)
Quality of Life of Living Kidney Donors in Germany: A Survey with the Validated Short Form-36 and Giessen Subjective Complaints List-24 Questionnaires (2004) (110)
Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer. (2004) (110)
Relationship between semen quality and the seminal plasma components carnitine, alpha-glucosidase, fructose, citrate and granulocyte elastase in infertile men compared with a normal population. (2000) (108)
Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer (2006) (106)
Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? (2000) (106)
Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma (2006) (104)
Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. (2004) (103)
Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte. (2006) (100)
Extracorporeal shock wave lithotripsy: multicenter study of kidney and upper ureter versus middle and lower ureter treatments. (1994) (98)
Laparoscopic radical prostatectomy. Technical aspects and experience with 125 cases. (2001) (98)
Laparoscopic radical nephrectomy: techniques, results and oncological outcome in 125 consecutive cases. (2004) (97)
Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. (1998) (96)
Bladder cancer: factors affecting survival. (1983) (96)
Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. (2001) (93)
Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer (2007) (93)
Comparison of transurethral resection to radical therapies for stage B bladder tumors. (1988) (90)
Morbidity from pelvic lymphadenectomy in staging carcinoma of the prostate. (1983) (90)
Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. (1999) (87)
Immunochemical detection of serum prostatic acid phosphatase. Methodology and clinical evaluation. (1978) (87)
Chemotherapy Programs of the National Prostatic Cancer Project (NPCP) (1980) (86)
Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. (2002) (85)
Laparoscopic live donor right nephrectomy: a new technique with preservation of vascular length. (2002) (84)
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. (1998) (84)
Cryosurgery in prostatic cancer: survival. (1982) (80)
Factors influencing the recurrence rate of bladder cancer. (1980) (78)
Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase‐1 and the complex of metalloproteinase‐1/tissue inhibitor in plasma of patients with prostate cancer (1997) (78)
Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. (1983) (77)
High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. (2005) (76)
Laparoscopic radical cystectomy with continent urinary diversion (rectosigmoid pouch) performed completely intracorporeally: an intermediate functional and oncologic analysis. (2004) (75)
Laparoscopic Pelvic Lymph Node Dissection for Genitourinary Malignancies: Indications, Techniques, and Results (1992) (74)
Laparoscopic partial nephrectomy in renal cell cancer--results and reproducibility by different surgeons in a high volume laparoscopic center. (2006) (74)
Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. (2007) (73)
Urogenital involvement by malignant lymphomas. (1981) (73)
The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model (2002) (72)
Laparoscopic radical prostatectomy--an analysis of factors affecting operating time. (2003) (72)
TP53 gene mutations in prostate cancer progression. (2010) (71)
Laparoscopic ureterolithotomy. (1998) (71)
Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells. (1997) (71)
Matrix‐metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma (2000) (68)
Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. (2000) (68)
A comparison between lymphangiography and pelvic node dissection in the staging of prostatic cancer. (1977) (67)
A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation. (1977) (67)
Analytical performance and clinical validity of two free prostate-specific antigen assays compared. (1996) (67)
Increased analytical sensitivity of RT‐PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood (1997) (66)
Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma (2007) (64)
"Old-for-old" cadaveric renal transplantation: surgical findings, perioperative complications and outcome. (2003) (63)
Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. (1981) (61)
Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. (1997) (59)
Polymerase chain reaction in the detection of micrometastases and circulating tumor cells (1996) (59)
Quantitative analysis of kallikrein 15 gene expression in prostate tissue. (2003) (59)
Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. (2008) (57)
Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. (2004) (56)
Primary adenocarcinoma of the bladder: a retrospective study of 20 patients. (1977) (55)
High dose rate brachytherapy of localized prostate cancer. (2002) (55)
Laparoscopic anatrophic nephrolithotomy (2004) (55)
Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99. (2005) (55)
Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. (2001) (55)
A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area. (1983) (54)
An artificial neural network considerably improves the diagnostic power of percent free prostate‐specific antigen in prostate cancer diagnosis: Results of a 5‐year investigation (2002) (54)
A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. (2003) (52)
A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. (2005) (52)
Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. (1979) (52)
In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma. (2006) (52)
Ureteral complications in the renal transplant recipient after laparoscopic living donor nephrectomy. (2006) (50)
Quantitative differences in matrix metalloproteinase (MMP)-2, but not in MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 or TIMP-2, in seminal plasma of normozoospermic and azoospermic patients. (2002) (48)
The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? (2004) (47)
Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. (2003) (47)
Thermoradiotherapy using interstitial self-regulating thermoseeds: an intermediate analysis of a phase II trial. (2004) (46)
1497: Use of Propsa within Artificial Neural Networks to Improve Prostate Cancer Specificity (2005) (45)
Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder (2006) (44)
Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells. (1998) (44)
The effect of the extracorporeal shock wave lithotriptor on the bone-cement interface in dogs. (1988) (44)
A (-5, -7) proPSA based artificial neural network to detect prostate cancer. (2006) (43)
Positive margins after laparoscopic radical prostatectomy: a prospective study of 100 cases performed by 4 different surgeons. (2003) (43)
Paraffinoma of the External Genitalia after Autoinjection of Vaseline (2000) (43)
Analysis of bladder tumor recurrence in 178 patients. (1980) (43)
Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. (1996) (42)
Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy (2005) (41)
The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. (1979) (40)
Nephrogenic adenoma: a report of 9 cases and review of the literature. (1982) (40)
A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate. (1981) (40)
Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers--investigation by temperature gradient gel electrophoresis (TGGE). (1997) (40)
Role of laparoscopic surgery in pediatric urology. (1997) (40)
Laparoscopic lymphocele drainage after renal transplantation. (1993) (40)
Sarcoma of the bladder and prostate. (1978) (39)
Flutamide in the treatment of metastatic carcinoma of the prostate. (1981) (39)
Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. (1999) (38)
Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: Association with progression and angiogenesis (2004) (38)
[Laparoscopic radical prostatectomy. Experiences with 145 interventions]. (2001) (36)
Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. (2006) (36)
Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: Analytical aspects (1998) (35)
TP53 gene mutations as an independent marker for urinary bladder cancer progression. (2008) (35)
Use of local anesthesia for extracorporeal shock wave lithotripsy. (1987) (34)
Extracorporeal shock wave lithotripsy in children. (1987) (34)
Use of percutaneous transperineal 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy (1993) (34)
Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. (2005) (33)
Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies. (2007) (32)
Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity (2004) (32)
The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. (1998) (32)
Laparoscopic excision of the sinusoidal remnants of the urachus in a 3-year-old boy. (1995) (32)
Laparoscopic versus open donor nephrectomy in Germany: impact on donor health-related quality of life and willingness to donate. (2005) (31)
Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. (2007) (31)
Gadolinium-enhanced three-dimensional magnetic resonance angiography versus conventional digital subtraction angiography: which modality is superior in evaluating living kidney donors? (2003) (31)
Dimethyl sulfoxide as additive in ready-to-use reaction mixtures for real-time polymerase chain reaction analysis with SYBR Green I dye. (2001) (29)
The frozen section in lymphadenectomy for carcinoma of the prostate. (1984) (29)
Evaluation of pedal lymphangiography in staging non-seminomatous testicular carcinoma. (1977) (29)
Preanalytical determinants of total and free prostate-specific antigen and their ratio: blood collection and storage conditions. (1998) (28)
Different Stability of Free and Complexed Prostate-Specific Antigen in Serum in Relation to Specimen Handling and Storage Conditions (2000) (28)
Radical prostatectomy with adjuvant radioactive gold for prostatic cancer: a preliminary report. (1985) (28)
Comparison of the Clinical Validity of Free Prostate–Specific Antigen, Alpha–1 Antichymotrypsin–Bound Prostate–Specific Antigen and Complexed Prostate–Specific Antigen in Prostate Cancer Diagnosis (2000) (27)
Adenocarcinoma of the urachus. (1978) (27)
Tumor M2 Pyruvate Kinase in Plasma of Patients with Urological Tumors (2001) (27)
Urinary cytology and bladder biopsy in patients with bladder cancer. (1978) (26)
Rapid detection of elevated prostate-specific antigen levels in blood: performance of various membrane strip tests compared. (1999) (26)
p53 Tumour Suppressor Gene Mutations in Benign Prostatic Hyperplasia and Prostate Cancer (1998) (26)
Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16. (2004) (26)
Urinary markers of malignancy. (2000) (26)
Sural nerve graft during laparoscopic radical prostatectomy. Initial experience. (2002) (25)
Cryosurgery in prostatic cancer: elimination of local lesion. (1983) (24)
Disease-free and overall survival after cryosurgical monotherapy for clinical stages B and C carcinoma of the prostate: a 20-year followup. (1997) (23)
High Expression of KLK14 in Prostatic Adenocarcinoma Is Associated with Elevated Risk of Prostate-Specific Antigen Relapse (2008) (23)
Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cells. (1996) (22)
Cryosurgery and immunotherapy for prostatic cancer. (1984) (22)
Kidney transplantation in children and adolescents. (2007) (22)
Repeating the measurement of prostate‐specific antigen in symptomatic men can avoid unnecessary prostatic biopsy (2003) (22)
Elimination of Serum Free and Total Prostate-Specific Antigen after Radical Retropubic Prostatectomy (1997) (22)
Re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 2007;51:1236- (2007) (22)
Orthotopic neobladder after kidney transplantation in a male patient with recurring urothelial carcinoma and renal cancer. (2001) (21)
Different prostate‐specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies (2007) (21)
Thermal ablation of canine prostate using interstitial temperature self-regulating seeds: new treatment for prostate cancer. (1997) (21)
Effect of thermal treatment on heating characteristics of Ni-Cu alloy for hyperthermia: preliminary studies. (1993) (21)
Acute partial segmental thrombosis of the corpus cavernosum: imaging findings on ultrasound, computed tomography, and magnetic resonance imaging. (2008) (21)
Percutaneous transperineal placement of gold 198 seeds for treatment of carcinoma of the prostate (1988) (20)
Radical prostatectomy and adjuvant radioactive gold seed placement: results of treatment at 5 and 10 years for clinical stages A2, B1 and B2 cancer of the prostate. (1991) (20)
mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue. (2003) (20)
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. (2004) (20)
What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood? (1996) (20)
Transverse colon conduit urinary diversion. (1982) (19)
Longitudinal study of bladder cancer with cytology and biopsy. (1978) (19)
ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation. (2000) (19)
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma. (2005) (18)
Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder. (2002) (18)
Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer. (2007) (18)
A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha1-antichymotrypsin-prostate- specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia. (1999) (18)
Increased frequency of lymphoceles under treatment with sirolimus following renal transplantation: a single center experience. (2002) (18)
Cryotherapy (1984) (18)
Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder. (2004) (18)
Prostate carcinoma metastatic to ureter. (1987) (18)
Laparoscopic live donor right nephrectomy: a new technique with preservation of vascular length. (2003) (18)
Interstitial hyperthermia using self-regulating thermoseeds combined with conformal radiation therapy. (2003) (18)
Interstitial Hyperthermia using Self-Regulating Thermoseeds Combined with Conformal Radiation Therapy (2002) (17)
Complete laparoscopic approach for radical cystectomy and continent urinary diversion (sigma rectum pouch). (2001) (17)
20-year experience with elderly donors in living renal transplantation. (2003) (17)
[Laparoscopic transperitoneal donor nephrectomy. Technique and results]. (2003) (17)
Urologic complications of pelvic exenteration for gynecologic malignancy. (1979) (16)
Tissue inhibitors of metalloproteinases 1 and 2 in human seminal plasma and their association with spermatozoa. (2002) (16)
A multicenter clinical trial on the use of alpha1‐antichymotrypsin‐prostate‐specific antigen in prostate cancer diagnosis (2001) (16)
Malignant androblastoma (Sertoli cell tumor) of the testis. A case report with a review of the literature. (1975) (16)
[MRI of prostate cancer using three different coil systems: image quality, tumor detection, and staging]. (2003) (15)
Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. (1996) (15)
Fibroadenoma of the urachus. (1974) (15)
The effect of interstitial hyperthermia on the Dunning prostate tumor model. (1992) (15)
Chemotherapy as an adjuvant to cystectomy and for advanced urothelial cancer. (1984) (15)
Serum markers in testicular tumors. (1979) (15)
Ureteral obstruction from Hodgkin's disease. (1974) (15)
Successful living related kidney transplantation despite renal angiomyolipoma in situ. (1999) (14)
[Laparoscopic radical cystectomy with intracorporeal creation of a continent urinary diversion. Future or present?]. (2002) (14)
Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used? (1998) (14)
[Thermal therapy of prostate cancer using magnetic nanoparticles]. (2007) (14)
Electrohydraulic shock wave lithotripsy (ESWL) fragmentation of retained common duct stones. (1988) (14)
Malignant tumours after renal transplantation. (1996) (14)
Determination of Non-α1-Antichymotrypsin-complexed Prostate-specific Antigen as an Indirect Measurement of Free Prostate-specific Antigen: Analytical Performance and Diagnostic Accuracy (2003) (14)
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate (1983) (14)
Laser-induced hyperthermia in rat prostate cancer: role of site of tumor implantation. (2000) (14)
Gold seed implantation in prostate brachytherapy. (1997) (13)
Genetic Analysis of Tp53 from Urine Sediment as a Tool for Diagnosing Recurrence and Residual of Bladder Carcinoma (2000) (13)
Laparoscopic living donor nephrectomy: from alternative to standard procedure. (2003) (13)
Soluble CD44 variants in the serum of patients with urological malignancies. (1997) (13)
Penile plexiform neurofibroma: case report and review of the literature. (1988) (13)
Survival of patients with localized prostate cancer treated with percutaneous transperineal placement of radioactive gold seeds: Stages A2, B, and C (1995) (13)
High-dose rate iridium192 afterloading therapy in combination with external beam irradiation for localized prostate cancer. (1997) (13)
Metalloproteinases and Tissue Inhibitors of Matrix‐Metalloproteinases in Plasma of Patients with Prostate Cancer and in Prostate Cancer Tissue (1999) (12)
Chemotherapy programs of the National Prostatic Cancer Project (NPCP). (1980) (12)
The in vivo effect of regional hyperthermia on dunning R3327 prostatic tumor (1991) (12)
Combination perineal cryosurgery and external radiation therapy for adenocarcinoma of prostate. (1984) (12)
Matrix metalloproteinase‐2 in blood does not indicate the progression of prostate cancer (1998) (11)
Relevance and meaning of prostate cancer in kidney transplantation. (2002) (11)
Percutaneous placement of radioactive gold seeds in localized prostatic carcinoma. (1987) (11)
Chemotherapy for advanced carcinoma of the bladder. (1981) (11)
Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: A re‐evaluation (2005) (11)
Kidney stones and renal transplantation. (1978) (11)
An adolescent with acute renal failure, thrombocytopenia and femoral vein thrombosis. (1998) (11)
New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics. (2006) (11)
Plasma concentrations of metalloproteinases (MMP-1, MMP-3) and their inhibitors in patients with prostate cancer (1998) (10)
[Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma]. (1998) (10)
Extracorporeal Shock Wave Lithotripsy for the Treatment of Urinary Calculi in the Elderly (1987) (10)
Laparoscopic donor nephrectomy in Germany. (2002) (10)
CD146 protein in prostate cancer: revisited with two different antibodies (2008) (9)
Laparoscopic pelvic lymph node dissection following definitive radiotherapy for carcinoma of the prostate. (1997) (9)
Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer. (2008) (9)
[Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis]. (2000) (9)
Diagnostic difficulties before definitive treatment of an extragonadal retroperitoneal germ cell tumor. (2001) (9)
Strip test for the quick detection of increased concentrations of prostate-specific antigen in blood. (1996) (9)
Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments. (2000) (9)
The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma (2010) (9)
Laparoscopic and Retroperitoneoscopic Radical Nephrectomy: Techniques and Outcome (2007) (9)
Revision Total Joint Arthroplasty Facilitated by Extracorporeal Shockwave Lithotripsy: A Case Report (1986) (9)
Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. (2005) (8)
[Thermoradiotherapy with interstitial thermoseeds in treatment of local prostatic carcinoma. Initial results of a phase II study]. (2001) (8)
Penile prostheses for the treatment of impotence. (1980) (8)
Optical coherence tomography of the urinary bladder: The potential of a high-resolution visual investigation technique for endoscopic diagnostics (2006) (8)
[The staging of bladder tumors in MRT: the value of the intravesical application of an iron oxide-containing contrast medium in combination with high-resolution T2-weighted imaging]. (2000) (8)
Metastatic tumors of the penis. (1979) (8)
Estramustine phosphate enhances the effects of hyperthermia and induces the small heat shock protein HSP27 in the human prostate carcinoma cell line PC-3 (2002) (8)
[An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l]. (2003) (8)
Fragmentation of biliary tract stones by lithotripsy using local anesthesia. (1988) (8)
Application of extracorporeal shock wave lithotripter (ECSWL) in orthopedics. I. Foundations and overview. (1991) (8)
Laparoscopic laser ureterolithotomy. (1994) (7)
Clinical course of patients with metastatic papillary renal cell carcinoma. (2006) (7)
Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer. (2003) (7)
STRATEGIEN IN DER BILDGEBENDEN DIAGNOSTIK DES HARNBLASENKARZINOMS (1999) (7)
Percutaneous Transperineal Placement of Radioactive Gold Seeds for Treatment of Localized Prostatic Carcinoma (1989) (7)
Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. (2000) (7)
TP 53 Gene Mutations in Prostate Cancer Progression (2010) (6)
The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells (2002) (6)
RE: A PROSPECTIVE STUDY TO EVALUATE THE ROLE OF COMPLEXED PROSTATE SPECIFIC ANTIGEN AND FREE/TOTAL PROSTATE SPECIFIC ANTIGEN RATIO FOR THE DIAGNOSIS OF PROSTATE CANCER (2002) (6)
Perineal cryosurgery of prostate cancer. (1981) (6)
Laparoscopic kidney harvesting for living donor kidney transplantation--one year follow-up of the initial 15 patients. (2001) (6)
The ratio of free to total prostate‐specific antigen in serum is correlated to the prostate volume (1996) (6)
Intrascrotal rhabdomyosarcoma. (1979) (6)
Recombinant factor VIIa for excessive bleeding after thrombectomy prior to kidney transplantation. (2004) (6)
Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats (2005) (6)
Kidney transplantation at the Charité: long tradition, elderly patients and the duration of hospitalization. (2002) (5)
Improved Technique for Placement of Interstitial Brachytherapy for Treatment of Prostate Cancer: Simultaneous High-Resolution Fluoroscopy and Transrectal Ultrasound (1992) (5)
The pharmacological effect of the gonadotrophin-releasing hormone on experimental cryptorchidism in rats. (1996) (5)
Rapid screening of PSA: evaluation of an immunochemical membrane strip test. (1995) (5)
Rubin H. Flocks and Colloidal Gold Treatments for Prostate Cancer (2011) (5)
Laparoscopic Partial Nephrectomy in Renal Cell Cancer—Indications, Technique, and Outcome in 80 Patients (2007) (5)
[Complications of laparoscopic interventions in urology]. (1996) (5)
In vivo and in vitro effects of shock waves on dunning prostate tumors (1988) (5)
Successful treatment of mediastinal seminoma with vinblastine, bleomycin, and cis-platinum. (1983) (5)
Brachytherapy and continuous infusion 5‐fluorouracil for the treatment of locally advanced, lymph node negative, prostate cancer: A phase I trial (1996) (5)
Effect of shock wave treatment on femoral prosthesis and cement removal. (1994) (5)
Cross-over kidney transplantation with simultaneous laparoscopic living donor nephrectomy: initial experience. (2008) (5)
Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics. (2007) (5)
Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma--results of a retrospective analysis. (2003) (5)
[Kidney donors and kidney transplantation in the elderly]. (2004) (5)
Effect of radiation and hyperthermia on prostate tumor cells with induced thermal tolerance and the correlation with HSP70 accumulation. (1996) (4)
Phase II study of amsacrine (AMSA) in previously treated patients with advanced transitional cell carcinoma of the urothelium: a National Bladder Cancer Collaborative Group A study. (1983) (4)
Living donor nephrectomy--no impact of genetic relationship. (2003) (4)
Sarcoma of the urinary bladder and prostate in children. (1978) (4)
Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis. (2000) (4)
Adjuvant chemotherapy to definitive treatment of prostate cancer (1980) (4)
Isoforms of prostate‐specific antigen in serum: A result of the glycosylation process in dysplastic prostatic cells? (1996) (4)
Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model (2006) (4)
Cystine calculi are radiopaque. (1980) (4)
912: Fluorescence Detection with 5-Aminolevulinic Acid (ALA) Reduces the Risk of Tumor Recurrence and Progression in Patients with Superficial Bladder Cancer: 5 Year Results of a Prospective Randomized Trial (2005) (4)
Interstitial hyperthermia using thermoseeds in combination with conformal radiotherapy for localized prostate cancer. (2002) (4)
Ureterovesical reflux in an adolescent and adult population. (1983) (4)
Urologic endoscopic surgery (1989) (4)
[Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer]. (2003) (3)
Minimally Invasive Urological Surgery (2005) (3)
Application of extracorporeal shock wave lithotripter (ECSWL) in orthopaedics. II. Dose-response and pressure distribution measurements. (1991) (3)
Alternative Therapien des lokalen Prostatakarzinoms (2001) (3)
Artificial ureteral replacement following kidney transplantation. (2006) (3)
Regional hyperthermia combined with high energy shock wave treatment on Dunning prostate tumors. (1990) (3)
Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. (1998) (3)
Soluble CD44 variants in serum of patients with prostate cancer and other urological malignancies (1996) (3)
[Radical prostatectomy in clinically localized prostate carcinoma. Pro laparoscopic approach]. (2002) (3)
β-Galactosidase as a marker of HSP70 promoter induction in Dunning R3327 prostate carcinoma cells (2004) (3)
Atlas of Laparoscopic Urologic Surgery (2023) (3)
Application of extracorporeal shock wave lithotripter (ECSWL) in orthopaedics. III. In vitro and in vivo studies. (1991) (3)
LAPAROSCOPIC URETEROLITHOTOMY - EXPERIENCE FROM 26 CASES (1999) (3)
Re: Editorial: can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies? (1997) (3)
[Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients]. (2000) (3)
COMMENT ON: CAN PROSTATE SPECIFIC ANTIGEN DERIVATIVES REDUCE THE FREQUENCYOF UNNECESSARY PROSTATE BIOPSIES BY PRESTIGIACOMO ET AL (1997) (3)
81 Iridium 192 afterloading, high dose rate brachytherapy of prostate cancer (2000) (3)
Multivisceral surgery for advanced gynaecological malignancies (2003) (3)
The value of alpha-fetoprotein and beta-human chorionic gonadotrophin in the management of testicular tumours. (1978) (3)
[Urological evaluation and follow-up of the kidney transplant patient]. (2006) (3)
Extracorporeal shock wave lithotripsy in paraplegic and quadriplegic patients. (1988) (3)
[Ten years of laparoscopic living kidney donation. From an extravagant to a routine procedure]. (2006) (2)
608: Comparison of Four Tumor Markers for Urinary Bladder Cancer- Tissue Polypeptide Antigen (TPA), HER-2/NEU (ERB B2), Urokinase-Type Plasminogen Activator Receptor (UPAR), and TP53 Mutation (2005) (2)
[MRI of the prostate after combined radiotherapy (afterloading and percutaneous): histopathologic correlation]. (2000) (2)
[Management of trauma to the male external genitalia]. (2006) (2)
714 THERMOTHERAPY USING MAGNETIC NANOPARTICLES IN PATIENTS WITH LOCALLY RECURRENT PROSTATE CANCER: RESULTS OF A PROSPECTIVE PHASE I TRIAL (2007) (2)
MATCH PAIR ANALYSIS HDR BRACHYTHERAPY VS. THERMORADIOTHERAPY USING INTERSTITIAL THERMOSEEDS (2006) (2)
255 RADIATION AND LONG-TERM HORMONAL THERAPY FOR PATIENTS WITH PROSTATE CANCER AND PATHOLOGICALLY CONFIRMED LYMPH NODE METASTASES (2007) (2)
Salmonella typhimurium prostatic abscess: a rare cause of persisting dysuria in an AIDS patient. (2003) (2)
A case report of a thymoma associated with a renal adenocarcinoma. (1980) (2)
208Evaluation of magnetic fluid hyperthermia (MFH) combined with external radiation in an orthotopic rat model of prostate cancer (2005) (2)
[Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis]. (2007) (2)
Rubin H. Flocks and colloidal gold treatments for prostate cancer. (2011) (2)
New Frontiers in Renal Cell Cancer (2007) (2)
Extracorporeal Shock Wave Lithotripsy in Para- and Quadriplegic Patients (1987) (2)
258: Diagnosis and Intraoperative Staging of Bladder Disease by in-vivo Optical Coherence Tomography (OCT) (2004) (2)
Percutaneous thrombolysis of an infected retroperitoneal hematoma with urokinase. (1995) (2)
Re: Lyndon Gommersall, Iqbal S. Shergill, Hashim U. Ahmed et al. Nanotechnology and its relevance to the urologist. Eur Urol 2007;52:368-75. (2008) (2)
[Quantifying gene expression in prostate carcinoma. Which endogenous reference genes are suitable?]. (2007) (2)
[Combined iridium 192 afterloading therapy of prostate carcinoma]. (1997) (2)
Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa. (1986) (2)
Laparoscopic dismembered pyeloplasty (2003) (2)
Repression of thermotolerance in Dunning R3327 prostate carcinoma cells by 2-deoxy-glucose (2004) (2)
[Experiences with laparoscopic lymphocele drainage]. (1994) (2)
805 PSA-VELOCITY AND ARTIFICIAL NEURAL NETWORK (ANN)-VELOCITY TO DIFFERENTIATE PROSTATE CANCER FROM BENIGN PROSTATIC DISEASE (2007) (1)
[Kidney transplantation in childhood and adolescence]. (2006) (1)
669: Laparoscopic Radical Cystectomy with Continent Urinary Diversion (Rectal Sigmoid Pouch) (2004) (1)
Papillary cystadenoma of kidney. (1973) (1)
Ex vivo and in vivo topographic studies of bladder by optical coherence tomography (Invited Paper) (2005) (1)
Beta-galactosidase as a marker of HSP70 promoter induction in Dunning R3327 prostate carcinoma cells. (1997) (1)
Laparoscopic donor nephrectomy (2005) (1)
Kind of Sample as Preanalytical Determinant of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitor of Metalloproteinase 2 in Blood, Matrix metalloproteinases and tissue inhibitors (1998) (1)
Auto-aggressive behavior after kidney transplantation. (2006) (1)
Bladder carcinoma at University of Iowa Hospital and Clinics. (1978) (1)
Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000. (2001) (1)
[Relevance of intraoperative frozen section diagnostics in urological surgery]. (2005) (1)
875Reducing the risk of cancer recurrence and progression in patients with superficial bladder tumour with 5-aminolevulinic acid-induced fluore scence diagnosis. Results of a prospective randomized 5-year study (2005) (1)
Sarcoma of the penis. (1980) (1)
[Value of radiotherapy in urology]. (2000) (1)
699 Phase II trial of paclitaxel and carboplatin in advanced/metastatic transitional cell cancer (2004) (1)
Abstracts of the 15th Congress of the European Society for Urological Research, Istanbul, October 5–7, 2000 (2000) (1)
105 HIGH EXPRESSION LEVELS OF THE HUMAN KALLIKREIN-LIKE PEPTIDASES KLK14 AND KLK 15 IN PROSTATIC ADENOCARCINOMA ARE ASSOCIATED WITH ELEVATED RISK OF PROSTATE-SPECIFIC ANTIGEN RELAPSE (2007) (1)
59 Combined interstitial and percutaneous radiotherapy for localized prostate cancer (1996) (1)
Extracorporeal shock wave lithotripsy. Noninvasive treatment for urinary stones. (1986) (1)
The essentials of minimally invasive urologic surgery (2005) (1)
Direct Effects of Shock Waves on Human Prostate Tissue (1988) (1)
Soluble CD44 Molecules in Serum of Patients with Cancer and Benign Prostatic Hyperplasia Prostate (1996) (1)
Re: Current status of local salvage therapies following radiation failure for prostate cancer. (2005) (1)
Impact of Extracorporeal Shock Wave Treatment on Dunning Prostate Tumors (1988) (1)
Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy. (2003) (1)
Dr. Bernhard Bargenda (2000) (0)
505 INDICATION OF BONE METASTASES IN PROSTATE CANCER PATIENTS AND THEIR SURVIVAL OUTCOME IN CORRELATION TO PLASMA OSTEOPONTIN AND OTHER BONE MARKERS (2007) (0)
1459: Expanding the Donor Pool in Kidney Transplantation - 7 Years Experience with Eurotransplant Senior Program (2006) (0)
Adult minimally invasive urologic surgery (2005) (0)
Laparoscopic adrenalectomy. (2019) (0)
CD59 expression in prostate cancer: a new marker of disease progression? (2004) (0)
965 METASTATIC PAPILLARY RENAL CELL CARCINOMA - IS THERE ANY RESPONSE TO IMMUNO- OR CHEMOTHERAPY? (2007) (0)
Pdt of Prostatecancer Pdt of Prostatecancer Analysis of Tumor Spillage during Radical Prostatectomy Using Rt-pcr of Prostate Specific Antigen. Expression of Vascular Endothelial Growth Factor and Its Receptors in the Rat Ventral Prostate and Dunning (0)
431 Non-myeloablative stem cell transplantation of metastatic renal cell cancer results in limited response rate but high toxicity (2004) (0)
1817: Artificial Ureteral Replacement Following Kidney Transplantation (2007) (0)
[Value of radiotherapy in urology]. (2000) (0)
147 Interstitial hyperthermia with self-regulating thermo-seeds in combination with conformal radiotherapy for prostate cancer — A phase II trial (2000) (0)
791The pure laparoscopic transperitoneal approach for living donor kidney explanatation — The charité Berlin experience with more than 100 cases (2005) (0)
INTERSTITIAL THERMOTHERAPY OF PROSTATE CANCER USING MAGNETIC NANOPARTICLES: RESULTS OF A PHASE I TRIAL (2006) (0)
Laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ cell tumour: Short term results from a high volume laparoscopy center (2003) (0)
THE ROLE OF HEAT SHOCK PROTEINS FOR VACCINATION MODELS IN RENAL CELL CARCINOMA (1999) (0)
159A retrospective analysis of two dose escalation regimen: Thermoradiotherapy using thermoseeds- vs. HDR-brachytherapy the charité experience (2005) (0)
Table 1. Correlation, mean, range, and mean differences of pairs of results for samples measured on the Variant Express and Diamat. (1999) (0)
Letter to the Editor Correspondence re: C. F. M. Sieret al., Enhanced Urinary Gelatinase Activities (Matrix Metalloproteinases 2 and 9) Are Associated with Early-Stage Bladder Carcinoma: A Comparison with Clinically Used Tumor (2001) (0)
Curriculum in Urology Renal Failure and Andrology (1998) (0)
199 - Percutaneous Placement of Radioactive AU198 Seeds for the Treatment of Prostate Cancer (1987) (0)
45 Late urethral complications after combined HDR brachytherapy and conformal radiotherapy for prostate cancer (1998) (0)
Original article Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer (2008) (0)
[Renal surgery--triumph for laparoscopy?]. (2003) (0)
INHIBITION OF GROWTH OF PROSTATE CANCER CELL LINES BY ENDOTHELIN RECEPTOR ANTAGONISTS (1999) (0)
Can complexed PSA improved the prostate cancer detection rate in men with a “non-suspicious” total PSA ange below 4 NG/ML? — Results of a multicenter trial (2003) (0)
Artificial urinary sphincter and penile prosthesis surgery: current status. (1984) (0)
Experience with germ cell tumors of testicle at University of Iowa. (1981) (0)
Confocal reflectance imaging of excised malignant human bladder biopsies (2004) (0)
Laparoscopic living donor nephrectomy 1-year-follow-up data of the initial 30 cases (2002) (0)
8 Laparoscopic vs. open donor nephrectomy - impact on quality of life and willingness to donate (2004) (0)
Identification of a Pharmacologically Active Metabolite of Mycophenolic Acid in Plasma of Transplant Recipi- Ents Treated with Mycophenolate Mofetil, Ekkehard (0)
Susceptibility of Renal Cell Carcinoma (RCC 7860) to In Situ Extracorporeal Shock Wave Neoplasmotripsy (1989) (0)
Drug therapy of genitourinary cancer. (1988) (0)
In vivo optical coherence tomography in endoscopic diagnostics of bladder disease (2004) (0)
625 COMPLICATIONS, URINARY CONTINENCE, AND ONCOLOGICAL OUTCOME (2007) (0)
OPTICAL COHERENCE TOMOGRAPHY (OCT) FOR THE DIAGNOSIS OF UROTHELIAL BLADDER CANCER: SENSITIVITY AND SPECIFICITY COMPARED TO WHITE LIGHT CYSTOSCOPY (2008) (0)
URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES: EDITORIAL COMMENT (1999) (0)
[Brachytherapy of local prostatic carcinoma]. (2001) (0)
1813: "Very Old" Donors for old Recipients - Outcome of Kidney Transplantation from Donors > 75 Years into Recipients > 65 Years (2007) (0)
Brachytherapy of Localized Prostate Cancer (2003) (0)
A NEW METHOD FOR STANDARDISED DIAGNOSIS FOLLOWING RENAL TRANSPLANTATION: CONTRAST ENHANCED ULTRASOUND (2006) (0)
DIAGNOSTIC VALIDITY OF VARIOUS MEMBRANE STRIP TESTS FOR RAPID DETECTION OF EVALUATED PSA-LEVEL (1999) (0)
132 The use of permanent interstitial temperature self-regulating rods for the treatment of prostate cancer (2000) (0)
994: Increased MRNA Expression of ADAMs (A Disintegrin and Metalloproteinase) in Renal Cell Carcinoma and their Association with Clinical Outcome (2004) (0)
350 POSTER Chass I histone deacetylase isoforms in prostate cancer: expression patterns in vivo and functional implications in vitro (2006) (0)
339Laparoscopic radical nephrectomy in renal cell cancer — Technique and oncological follow-up in 170 cases (2005) (0)
Minimally invasive treatments for bladder cancer – from transurethral resection to laparoscopic radical cystectomy (2005) (0)
Extracorporeal Shock Wave Lithotripsy in the Treatment of Large Common Bile Duct Stones (1988) (0)
Subject Index Vol. 38, 2000 (2000) (0)
The effects of visual fluorescence marking induced by 5-aminolevulinic acid for endoscopic diagnosis of urinary bladder cancer (2003) (0)
Laproscopic radical prostatectomy: nerve-sparing technique (2002) (0)
High-dose rate brachytherapy--the Charité experience. (2002) (0)
Oncology: Prostate/Testis/Penis/Urethra A MULTICENTER CLINICAL TRIAL ON THE USE OF (-5, -7) PRO PROSTATE SPECIFIC ANTIGEN (2005) (0)
LAPAROSCOPIC PARTIAL NEPHRECTOMY IN RENAL CELL CANCER – INDICATIONS, TECHNIQUE, AND OUTCOME IN 102 CONSECUTIVE CASES (2008) (0)
Acknowledgement to reviewers (1998) (0)
713Laparoscopic radical cystectomy with rectosigmoid pouch, an intermediate functional and oncological analysis (2005) (0)
Comprar Atlas of Laparoscopic Urologic Surgery | Robert G. Moore | 9781841845418 | Informa Healthcare (2007) (0)
163Thermoradiotherapy using intersiitial self regulating thermoseeds (2005) (0)
MATRIX METALLOPROTEINASES (MMP) AND TISSUE INHIBITORS OF MMP (TIMP) IN RENAL CELL CARCINOMA (1999) (0)
637Endoscopic diagnosis of bladder disease with optical coherence tomography (OCT) (2005) (0)
Advanced cecal carcinoma mimicking Peyronie's disease. (2004) (0)
4 Transplanting cadaveric kidneys from old donors into old recipients — Good results with a lot of complications (2004) (0)
1953: Transplanting Cadaveric Kidneys from Old Donors into Old Recipients - Good Renal Function with Significant Morbidity (2004) (0)
Thermoradiotherapy with interstitial thermoseeds for localised prostate cancer (2002) (0)
Response and survival following chemoimmunotherapy for metastatic renal cell carcinoma in 107 consecutive patients - results of a retrospective single center analysis (2003) (0)
Pelvic lymphadenectomy for carcinoma of prostate. (1985) (0)
The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. (1978) (0)
Constitutional symptoms in patients with germ cell neoplasms. (1990) (0)
819: Laparoscopic Transperitoneal Radical Prostatectomy-Reproducibility in a Single Center Experience (2004) (0)
Laparoscopic retroperitoneal lymphadenectomy - a routine therapeutic modality in the treatment of nonseminomatons testis cancer stage I (2002) (0)
Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. (1999) (0)
ASSOCIATION OF CHROMOSOME 13 q COPY NUMBER LOSSES WITH TUMOR PROGRESSION IN PROSTATE CANCER (PC) (1999) (0)
[Alternative therapies of local prostatic carcinoma]. (2001) (0)
Methods in molecular biology: minor errors in primer citations with major consequences: how can we minimize these mistakes? (2000) (0)
Learning curve for laparoscopic radical prostatectomy: A prospective analysis of 100 cases (2003) (0)
[New serum markers of bone metastasis in prostate carcinoma]. (2007) (0)
MUTATION OF THE TUMOR SUPPRESSOR GENE p53 IN HUMAN TEMPERATURE GRADIENT GEL ELECTROPHORESIS (TGGE) PROSTATE AND BLADDER CANCERS-INVESTIGATION BY (1997) (0)
HSP 70 induction and thermotolerance following interstitial hyperthermia in the dunning R3327 tumor in vivo. (1997) (0)
Treatment of Localized Carcinoma of the Prostate with Percutaneous Perineal AU 198 (1987) (0)
[Taxanes in the chemotherapy of hormone-refractory prostate carcinoma]. (2004) (0)
Laparoscopic diagnosis and therapy of an undescended testicle after renal transplantation. (1995) (0)
[Tumor suppressor RECK in prostate carcinoma. Decreased RECK expression as indicator of proteolytic imbalance]. (2007) (0)
343Laparoscopic partial nephrectomy in renal cell cancer — Results and reproducibility by different surgeons in a high volume laparoscopic center (2005) (0)
836 Thermoradiotherapy using interstitial self regulating thermoseeds — an intermediate analysis of a phase II trial (2004) (0)
1068: TP53 Gene Mutations as a Prognostic Marker for PSA Progression in Early Stage Prostate Cancer (2004) (0)
157High dose rate (HDR) brachytherapy of localized prostate cancer (2005) (0)
920Metastatic papillary renal cell carcinoma - Is there any response to immunotherapy? (2005) (0)
797What to do with nephrolithiasis in the living kidney donor? A survey of the german kidney transplantation centres (2005) (0)
THERMOTHERAPY USING MAGNETIC NANOPARTICLES IN PATIENTS WITH LOCALLY RECURRENT PROSTATE CANCER: INITIAL RESULTS OF A PHASE I STUDY (2006) (0)
802 DIFFERENT PSA ASSAYS GIVE DIFFERENT RESULTS ON THE SAME BLOOD SAMPLE -A SERIOUS OBSTACLE TO RECOMMEND UNIFORM LIMITS FOR PROSTATE BIOPSIES (2007) (0)
Contents Vol. 38, 2000 (2000) (0)
COMMENT ON: FREE AND COMPLEXED PROSTATE SPECIFIC ANTIGEN IN THE DIFFERENTIATION OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER : STUDIES IN SERUM AND PLASMA SAMPLES. AUTHORS' REPLY (1999) (0)
Positive margins following laparoscopic radical prostatectomy - a prospective analysis of 100 cases (2003) (0)
[New serum markers in prostate carcinoma and their application to artificial neural networks]. (2007) (0)
EFFECTIVITY OF OPTICAL COHERENCE TOMOGRAPHY FOR THE DIAGNOSIS OF UROTHELIAL BLADDER CANCER (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stefan A. Loening?

Stefan A. Loening is affiliated with the following schools:

Stefan A. Loening's Academic­Influence.com Rankings

Stefan A. Loening's Degrees

Why Is Stefan A. Loening Influential?

Stefan A. Loening's Published Works

Published Works

What Schools Are Affiliated With Stefan A. Loening?

Stefan A. Loening's AcademicInfluence.com Rankings